Statin therapy for elevated hsCRP: what are the public health implications?
Ridker
Paul M
PM
Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA 02215, USA. pridker@partners.org
D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis / Q000187:drug effects*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D005464:Fluorobenzenes / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D011634:Public Health / Q000191:economics* / Q000639:trends; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use; D014481:United States
D000924:Anticholesteremic Agents; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein